Table Info

Table 1.

ACAT inhibitors for anti-atherosclerosis purpose

Inhibitors	Ki (μmol/L)		Status
Inhibitors	ACAT1	ACAT2	Status
CI976	5.9	2.1	Failed at pre-clinical stage (Parke-Davis)
ATR101 (nevanimibe)	0.23		Failed at pre-clinical stage (Parke-Davis)
CP113818	0.02	0.02	Failed at pre-clinical stage (Pfizer)
CI1011	19	19	Abandoned after phase 3 (Pfizer)
CS505 (pactimibe)	4.9	3	Abandoned after phase 3 (Sankyo)
K604	0.45	102.9	Abandoned after phase 2 trial (Kowa)
F12511	0.039	0.11	Abandoned after phase 1 trial (Lilly)

Declarations

Author contributions

TYC and CCYC provided conception and design of the review; TYC wrote the first draft of the manuscript. All other authors were involved in discussing the conception and design of the review, and in collecting key references. All authors read, edited, and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This work is supported financially by NIH grant AG AG037609 to TYC and CCYC. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Chang TY, Yamauchi Y, Hasan MT, Chang C. Cellular cholesterol homeostasis and Alzheimer’s disease. J Lipid Res. 2017;58:2239–54. [DOI] [PubMed] [PMC]

Storch J, Xu Z. Niemann-pick C2 (NPC2) and intracellular cholesterol trafficking. Biochim Biophys Acta. 2009;1791:671–8. [DOI] [PubMed] [PMC]

Pfeffer SR. NPC intracellular cholesterol transporter 1 (NPC1)-mediated cholesterol export from lysosomes. J Biol Chem. 2019;294:1706–9. [DOI] [PubMed] [PMC]

Urano Y, Watanabe H, Murphy SR, Shibuya Y, Geng Y, Peden AA, et al. Transport of LDL-derived cholesterol from the NPC1 compartment to the ER involves the trans-Golgi network and the SNARE protein complex. Proc Natl Acad Sci U S A. 2008;105:16513–8. [DOI] [PubMed] [PMC]

Reverter M, Rentero C, de Muga SV, Alvarez-Guaita A, Mulay V, Cairns R, et al. Cholesterol transport from late endosomes to the Golgi regulates t-SNARE trafficking, assembly, and function. Mol Biol Cell. 2011;22:4108–23. [DOI] [PubMed] [PMC]

Liscum L, Dahl NK. Intracellular cholesterol transport. J Lipid Res. 1992;33:1239–54. [DOI] [PubMed]

Yamauchi Y, Yokoyama S, Chang TY. ABCA1-dependent sterol release: sterol molecule specificity and potential membrane domain for HDL biogenesis. J Lipid Res. 2016;57:77–88. [DOI] [PubMed] [PMC]

Abi-Mosleh L, Infante RE, Radhakrishnan A, Goldstein JL, Brown MS. Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport of cholesterol in Niemann-pick type C cells. Proc Natl Acad Sci U S A. 2009;106:19316–21. [DOI] [PubMed] [PMC]

Yamauchi Y, Iwamoto N, Rogers MA, Abe-Dohmae S, Fujimoto T, Chang CCY, et al. Deficiency in the lipid exporter ABCA1 impairs retrograde sterol movement and disrupts sterol sensing at the endoplasmic reticulum. J Biol Chem. 2015;290:23464–77. [DOI] [PubMed] [PMC]

10.

Das A, Brown MS, Anderson DD, Goldstein JL, Radhakrishnan A. Three pools of plasma membrane cholesterol and their relation to cholesterol homeostasis. Elife. 2014;3:e02882. [DOI] [PubMed] [PMC]

11.

Mesmin B, Pipalia NH, Lund FW, Ramlall TF, Sokolov A, Eliezer D, et al. STARD4 abundance regulates sterol transport and sensing. Mol Biol Cell. 2011;22:4004–15. [DOI] [PubMed] [PMC]

12.

Garbarino J, Pan M, Chin HF, Lund FW, Maxfield FR, Breslow JL. STARD4 knockdown in HepG2 cells disrupts cholesterol trafficking associated with the plasma membrane, ER, and ERC. J Lipid Res. 2012;53:2716–25. [DOI] [PubMed] [PMC]

13.

Sandhu J, Li S, Fairall L, Pfisterer SG, Gurnett JE, Xiao X, et al. Aster proteins facilitate nonvesicular plasma membrane to ER cholesterol transport in mammalian cells. Cell. 2018;175:514–29.e20. [DOI] [PubMed] [PMC]

14.

Naito T, Ercan B, Krshnan L, Triebl A, Koh DHZ, Wei FY, et al. Movement of accessible plasma membrane cholesterol by the GRAMD1 lipid transfer protein complex. Elife. 2019;8:e51401. [DOI] [PubMed] [PMC]

15.

Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14:388–405. [DOI] [PubMed] [PMC]

16.

Foley P. Lipids in Alzheimer’s disease: a century-old story. Biochim Biophys Acta. 2010;1801:750–3. [DOI] [PubMed]

17.

Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron. 2010;68:270–81. [DOI] [PubMed]

18.

Beecham GW, Hamilton K, Naj AC, Martin ER, Huentelman M, Myers AJ, et al. Genome-wide association meta-analysis of neuropathologic features of Alzheimer’s disease and related dementias. PLoS Genet. 2014;10:e1004606. [DOI] [PMC]

19.

Nordestgaard LT, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Loss-of-function mutation in ABCA1 and risk of Alzheimer’s disease and cerebrovascular disease. Alzheimers Dement. 2015;11:1430–8. [DOI] [PubMed]

20.

Sienski G, Narayan P, Bonner JM, Kory N, Boland S, Arczewska AA, et al. APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia. Sci Transl Med. 2021;13:eaaz4564. [DOI] [PubMed] [PMC]

21.

Guttenplan KA, Weigel MK, Prakash P, Wijewardhane PR, Hasel P, Rufen-Blanchette U, et al. Neurotoxic reactive astrocytes induce cell death via saturated lipids. Nature. 2021;599:102–7. [DOI] [PubMed]

22.

Wang H, Kulas JA, Wang C, Holtzman DM, Ferris HA, Hansen SB. Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol. Proc Natl Acad Sci U S A. 2021;118:e2102191118. [DOI] [PubMed] [PMC]

23.

Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA, et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem. 2012;287:2678–88. [DOI] [PubMed] [PMC]

24.

Tajima Y, Ishikawa M, Maekawa K, Murayama M, Senoo Y, Nishimaki-Mogami T, et al. Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer’s disease. Lipids Health Dis. 2013;12:68. [DOI] [PubMed] [PMC]

25.

van der Kant R, Langness VF, Herrera CM, Williams DA, Fong LK, Leestemaker Y, et al. Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-beta in iPSC-derived Alzheimer’s disease neurons. Cell stem cell. 2019;24:363–75.e9. [DOI] [PubMed] [PMC]

26.

Brown MS, Ho YK, Goldstein JL. The cholesteryl ester cycle in macrophage foam cells. Continual hydrolysis and re-esterification of cytoplasmic cholesteryl esters. J Biol Chem. 1980;255:9344–52. [DOI] [PubMed]

27.

Chang CC, Huh HY, Cadigan KM, Chang TY. Molecular cloning and functional expression of human acyl-coenzyme A:cholesterol acyltransferase cDNA in mutant Chinese hamster ovary cells. J Biol Chem. 1993;268:20747–55. [DOI] [PubMed]

28.

Anderson RA, Joyce C, Davis M, Reagan JW, Clark M, Shelness GS, et al. Identification of a form of acyl-CoA:cholesterol acyltransferase specific to liver and intestine in nonhuman primates. J Biol Chem. 1998;273:26747–54. [DOI] [PubMed]

29.

Cases S, Novak S, Zheng YW, Myers HM, Lear SR, Sande E, et al. ACAT-2, a second mammalian acyl-CoA:cholesterol acyltransferase. Its cloning, expression, and characterization. J Biol Chem. 1998;273:26755–64. [DOI] [PubMed]

30.

Oelkers P, Behari A, Cromley D, Billheimer JT, Sturley SL. Characterization of two human genes encoding acyl coenzyme A:cholesterol acyltransferase-related enzymes. J Biol Chem. 1998;273:26765–71. [DOI] [PubMed]

31.

Liu J, Chang CCY, Westover EJ, Covey DF, Chang TY. Investigating the allosterism of acyl CoA:cholesterol acyltransferase (ACAT) by using various sterols: in vitro and intact cell studies. Biochem J. 2005;391:389–97. [DOI] [PubMed] [PMC]

32.

Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell. 2006;124:35–46. [DOI] [PubMed]

33.

Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161:161–72. [DOI] [PubMed] [PMC]

34.

Chang CC, Chen J, Thomas MA, Cheng D, Del Priore VA, Newton RS, et al. Regulation and immunolocalization of acyl-coenzyme A: cholesterol acyltransferase in mammalian cells as studied with specific antibodies. J Biol Chem. 1995;270:29532–40. [DOI] [PubMed]

35.

Cheng D, Chang CC, Qu X, Chang TY. Activation of acyl-coenzyme A:cholesterol acyltransferase by cholesterol or by oxysterol in a cell-free system. J Biol Chem. 1995;270:685–95. [DOI] [PubMed]

36.

Chang TY, Li BL, Chang CCY, Urano Y. Acyl-coenzyme A:cholesterol acyltransferases. Am J Physiol Endocrinol Metab. 2009;297:E1–9. [DOI] [PubMed] [PMC]

37.

Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT, et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol. 2001;3:905–12. [DOI] [PubMed]

38.

Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, et al. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer’s disease. Neuron. 2004;44:227–38. [DOI] [PubMed]

39.

Bryleva EY, Rogers MA, Chang CCY, Buen F, Harris BT, Rousselet E, et al. ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci U S A. 2010;107:3081–6. [DOI] [PubMed] [PMC]

40.

Murphy SR, Chang CC, Dogbevia G, Bryleva EY, Bowen Z, Hasan MT, et al. ACAT1 knockdown gene therapy decreases amyloid-beta in a mouse model of Alzheimer’s disease. Mol Ther. 2013;21:1497–506. [DOI] [PubMed] [PMC]

41.

Shibuya Y, Chang CCY, Huang LH, Bryleva EY, Chang TY. Inhibiting ACAT1/SOAT1 in microglia stimulates autophagy-mediated lysosomal proteolysis and increases Aβ1–42 clearance. J Neurosci. 2014;34:14484–501. [DOI] [PubMed] [PMC]

42.

Nugent AA, Lin K, van Lengerich B, Lianoglou S, Przybyla L, Davis SS, et al. TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge. Neuron. 2020;105:837–54.e9. [DOI] [PubMed]

43.

Shibuya Y, Niu Z, Bryleva EY, Harris BT, Murphy SR, Kheirollah A, et al. Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer’s disease mouse and reduces human P301L-tau content at the presymptomatic stage. Neurobiol Aging. 2015;36:2248–59. [DOI] [PubMed] [PMC]

44.

Shibuya Y, Chang CC, Chang TY. ACAT1/SOAT1 as a therapeutic target for Alzheimer’s disease. Future Med Chem. 2015;7:2451–67. [DOI] [PubMed] [PMC]

45.

Hong S, Dissing-Olesen L, Stevens B. New insights on the role of microglia in synaptic pruning in health and disease. Curr Opin Neurobiol. 2016;36:128–34. [DOI] [PubMed] [PMC]

46.

Loving BA, Bruce KD. Lipid and lipoprotein metabolism in microglia. Front Physiol. 2020;11:393. [DOI] [PubMed] [PMC]

47.

Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O’Keeffe S, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929–47. [DOI] [PubMed] [PMC]

48.

Lei L, Xiong Y, Chen J, Yang JB, Wang Y, Yang XY, et al. TNF-alpha stimulates the ACAT1 expression in differentiating monocytes to promote the CE-laden cell formation. J Lipid Res. 2009;50:1057–67. [DOI] [PubMed] [PMC]

49.

Lange Y, Steck TL. Active membrane cholesterol as a physiological effector. Chem Phys Lipids. 2016;199:74–93. [DOI] [PubMed]

50.

Oram JF, Heinecke JW. ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev. 2005;85:1343–72. [DOI] [PubMed]

51.

Yamauchi Y, Chang CCY, Hayashi M, Abe-Dohmae S, Reid PC, Chang TY, et al. Intracellular cholesterol mobilization involved in the ABCA1/apolipoprotein-mediated assembly of high density lipoprotein in fibroblasts. J Lipid Res. 2004;45:1943–51. [DOI] [PubMed]

52.

Alavez-Rubio JS, Martinez-Rodriguez N, Escobedo-de-la-Pena J, Garrido-Acosta O, Juarez-Cedillo T. Relationship between genetic variants of ACAT1 and APOE with the susceptibility to dementia (SADEM Study). Mol Neurobiol. 2021;58:905–12. [DOI] [PubMed]

53.

Li BL, Li XL, Duan ZJ, Lee O, Lin S, Ma ZM, et al. Human acyl-CoA:cholesterol acyltransferase-1 (ACAT-1) gene organization and evidence that the 4.3-kilobase ACAT-1 mRNA is produced from two different chromosomes. J Biol Chem. 1999;274:11060–71. [DOI] [PubMed]

54.

Wollmer MA, Streffer JR, Tsolaki M, Grimaldi LME, Lutjohann D, Thal D, et al. Genetic association of acyl-coenzyme A: cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load, and risk for Alzheimer’s disease. Mol Psychiatry. 2003;8:635–8. [DOI] [PubMed]

55.

Tardif JC, Gregoire J, L’Allier PL, Anderson TJ, Bertrand O, Reeves F, et al. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation. 2004;110:3372–7. [DOI] [PubMed]

56.

Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med. 2006;354:1253–63. [DOI] [PubMed]

57.

Sahi J, Milad MA, Zheng X, Rose KA, Wang H, Stilgenbauer L, et al. Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor. J Pharmacol Exp Ther. 2003;306:1027–34. [DOI] [PubMed]

58.

Riddell D, Bright CP, Burton BJ, Bush RC, Harris NV, Hele D, et al. Hypolipidaemic properties of a potent and bioavailable alkylsulphinyl-diphenylimidazole ACAT inhibitor (RP 73163) in animals fed diets low in cholesterol. Biochem Pharmacol. 1996;52:1177–86. [DOI] [PubMed]

59.

Sliskovic DR, Picard JA, Krause BR. ACAT inhibitors: the search for a novel and effective treatment of hypercholesterolemia and atherosclerosis. Prog Med Chem. 2002;39:121–71. [DOI] [PubMed]

60.

Meiner VL, Cases S, Myers HM, Sande ER, Bellosta S, Schambelan M, et al. Disruption of the acyl-CoA:cholesterol acyltransferase gene in mice: evidence suggesting multiple cholesterol esterification enzymes in mammals. Proc Natl Acad Sci U S A. 1996;93:14041–6. [DOI] [PubMed] [PMC]

61.

Burnett JR. Eflucimibe. Pierre Fabre/Eli Lilly. Curr Opin Investig Drugs. 2003;4:347–51. [PubMed]

62.

Lopez-Farre AJ, Sacristan D, Zamorano-Leon JJ, San-Martin N, Macaya C. Inhibition of acyl-CoA cholesterol acyltransferase by F12511 (eflucimibe): could it be a new antiatherosclerotic therapeutic? Cardiovasc Ther. 2008;26:65–74. [DOI] [PubMed]

63.

Ikenoya M, Yoshinaka Y, Kobayashi H, Kawamine K, Shibuya K, Sato F, et al. A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis. 2007;191:290–7. [DOI] [PubMed]

64.

Hudry E, Vandenberghe LH. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron. 2019;101:839–62. [DOI] [PubMed]

65.

Carstea ED, Morris JA, Coleman KG, Loftus SK, Zhang D, Cummings C, et al. Niemann-pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science. 1997;277:228–31. [DOI] [PubMed]

66.

Naureckiene S, Sleat DE, Lackland H, Fensom A, Vanier MT, Wattiaux R, et al. Identification of HE1 as the second gene of Niemann-pick C disease. Science. 2000;290:2298–301. [DOI] [PubMed]

67.

Ho WY, Chang JC, Lim K, Cazenave-Gassiot A, Nguyen AT, Foo JC, et al. TDP-43 mediates SREBF2-regulated gene expression required for oligodendrocyte myelination. J Cell Biol. 2021;220:e201910213. [DOI] [PubMed]

68.

Valenza M, Carroll JB, Leoni V, Bertram LN, Bjorkhem I, Singaraja RR, et al. Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Hum Mol Genet. 2007;16:2187–98. [DOI] [PubMed]

69.

Leoni V, Caccia C. The impairment of cholesterol metabolism in Huntington disease. Biochim Biophys Acta. 2015;1851:1095–105. [DOI] [PubMed]

70.

Bemlih S, Poirier MD, El Andaloussi A. Acyl-coenzyme A: cholesterol acyltransferase inhibitor Avasimibe affect survival and proliferation of glioma tumor cell lines. Cancer Biol Ther. 2010;9:1025–32. [DOI] [PubMed]

71.

Ohmoto T, Nishitsuji K, Yoshitani N, Mizuguchi M, Yanagisawa Y, Saito H, et al. K604, a specific acyl CoA:cholesterol acyltransferase 1 inhibitor, suppresses proliferation of U251 MG glioblastoma cells. Mol Med Rep. 2015;12:6037–42. [DOI] [PubMed]